Skip to main content

Illinois IGB

Paul Hergenrother

Unprecedented Compound Takes a Step Toward Breast Cancer Clinical Trials

November 21, 2023

Estrogen receptor-positive breast cancer is the most common form of breast cancer, affecting approximately 75% of breast cancer patients. In advanced and metastatic form, it is lethal, claiming the lives of nearly 350,000 individuals annually. Presently, no drug is able to eradicate these advanced tumors.


November 21, 2023


Related Articles

Team identifies key driver of cancer cell death pathway that activates immune cells

July 31, 2023

Scientists have identified a protein that plays a critical role in the action of several emerging cancer therapies. The researchers say the discovery will likely aid efforts to fine-tune the use of immunotherapies against several challenging cancers. They report their findings in the journal Cancer Research


July 31, 2023


Related Articles

First test of anti-cancer agent PAC-1 in human clinical trials shows promise

December 22, 2022

A phase I clinical trial of PAC-1, a drug that spurs programmed cell death in cancer cells, found only minor side effects in patients with end-stage cancers. The drug stalled the growth of tumors in the five people in the trial with neuroendocrine cancers and reduced tumor size in two of those patients. It also showed some therapeutic activity against sarcomas, scientists and clinicians report in the British Journal of Cancer.


December 22, 2022


Related Articles

SHIELD program a model for effective pandemic management, data show

June 13, 2022

In the fall of 2020, the University of Illinois Urbana-Champaign welcomed students back for in-person instruction amid the powerful first wave of the COVID-19 pandemic. The university successfully maintained operations throughout the semester – with zero COVID-19-related deaths or hospitalizations in the campus community – thanks to its “SHIELD: Target, Test, Tell” program.


June 13, 2022


Related Articles

15 Years of IGB: SHIELDing the Illinois community against COVID-19

May 11, 2022

During the earliest months of 2020, COVID-19 seemed like an innocuous event that was too geographically distant to affect the Illinois community. In fact, by March 10th there were only 19 confirmed cases. Nevertheless, Nigel Goldenfeld (BCXT leader/GNDP), former Swanlund Endowed Chair and professor of physics, and Sergei Maslov (BCXT/CABBI), a professor of bioengineering and Bliss Faculty Scholar, were worried. The news from China and Italy was concerning and in four days a significant portion of students, faculty, and staff were going to leave for spring break.


May 11, 2022


Related Articles

Scientists discover how antibiotics penetrate Gram-negative bacterial cell walls

November 8, 2021

Scientists have labored for decades to find antibiotics that work against Gram-negative bacteria, which cause some of the deadliest infections in hospital settings and are most likely to be resistant to treatment with existing antibiotics. In a study reported in the journal Chemical Science, researchers developed a new method to determine how antibiotics with specific chemical properties thread their way through tiny pores in the otherwise impenetrable cell envelopes of Gram-negative bacteria.


November 8, 2021


Related Articles

10 IGB members receive Presidential Medallion

August 23, 2021

August 23, 2021


Related Articles

New approach eradicates breast cancer in mice

July 21, 2021

A new approach to treating breast cancer kills 95-100% of cancer cells in mouse models of human estrogen-receptor-positive breast cancers and their metastases in bone, brain, liver and lungs. The newly developed drug, called ErSO, quickly shrinks even large tumors to undetectable levels.

Led by scientists at the University of Illinois Urbana-Champaign, the research team reports the findings in the journal Science Translational Medicine.


July 21, 2021


Related Articles

Subscribe to Paul Hergenrother